{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-009352","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2025-07-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.837827+00:00","generated_at":"2026-05-18T04:12:44.106237+00:00","sec_items":["1.01","8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"FDA grants Fast Track for PMN310; ATM program terminated after minimal sales","bullets":["FDA granted Fast Track Designation to PMN310 for Alzheimer's disease.","DSMB approved dose escalation to second 10 mg/kg cohort in Phase 1b trial (May 2025).","No cases of ARIA (brain swelling/microhemorrhages) observed as of July 21, 2025.","ATM program with BTIG terminated; only $190,274 raised of $25M available (75,862 shares sold).","No termination penalties; no further shares will be sold under the program."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-009352","json":"https://secwatch.observer/filing/0001558370-25-009352.json","markdown":"https://secwatch.observer/filing/0001558370-25-009352.md","text":"https://secwatch.observer/filing/0001558370-25-009352.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000155837025009352/0001558370-25-009352-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000155837025009352/pmn-20250721x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T04:12:44.106237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}